Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Shanghai City, China Clinical Trials

A listing of Shanghai City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (859) clinical trials

A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW

To evaluate the safety and efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) compared to the PTA catheter (AMPHIRION DEEP) in treatment of stenosis or occlusion inbelow the knee artery. This is a prospective, multi-center, randomized, control, opening, superiority designed clinical study. Plan to enroll 172 eligible subjects …

Phase N/A

0.0 miles

Learn More »

Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds

This is a randomized, split face, multicenter study to evaluate the efficacy and safety of Restylane Defyne compared to Restylane in correction of NLFs.

Phase N/A

0.0 miles

Learn More »

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction …

Phase

0.0 miles

Learn More »

Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain

This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine …

Phase

0.0 miles

Learn More »

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1001 in subjects with advanced solid tumors.

Phase

0.0 miles

Learn More »

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

This study plans to enroll triple-negative breast cancer patients who have complete tumor removal. Patients are randomized to receive either EC-wP/T or EC-wP/TCb adjuvant chemotherapy. For triple-negative breast cancer, a subgroup of triple-negative breast cancer has DNA repairement deficiency and adding carboplatin to paclitaxel may improve DFS on the basis …

Phase

0.0 miles

Learn More »

The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections

Surgery is the primary treatment of lung cancer, but surgery releases tumor cells into the systemic circulation. Whether this minimal residual disease results in clinical metastases is a function of host defense. At least three perioperative factors shift the balance toward initiation and progression of minimal residual disease. Surgery per …

Phase N/A

0.0 miles

Learn More »

Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

Cervical carcinoma is one of the most common gynecologic cancers worldwide. The prognosis of cervical cancer is favorable, with around 80-90% 5-year survival rate in early stage disease. However, advanced disease carries a poor prognosis. Current standard treatment for locally advanced cervical cancer, which is not eligible for surgical treatment, …

Phase

0.0 miles

Learn More »

Adjuvant IFN- for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression

BACKGROUND: Postoperative interferon-alpha (IFN-alpha) therapy improved survival in patients with hepatocellular carcinoma (HCC). MiR-26 is a predictive marker for the effect of postoperative interferon-alpha treatment in patients with HCC. Our study is to identify the effect of postoperative IFN-alpha treatment in patients with a low miR-26 expression in tumor after …

Phase

0.0 miles

Learn More »

Rapamycin Treatment for Activated Phosphoinositide 3-Kinase Syndrome

Activated phosphoinositide 3-kinase syndrome (APDS) is a recently described autosomal dominant primary immunodeficiency (PID), caused by the mutations in PIK3CD gene. The manifestations of APDS mainly include recurrent respiratory tract infections, persistent Epstein-Barr virus (EBV)/ cytomegalovirus (CMV)infections, lymphadenopathy, splenomegaly, CD4+T cells lymphopenia, and hyper-IgM syndrome. PIK3CD encodes p110, the catalytic …

Phase

0.0 miles

Learn More »